Exact Sciences — Nov 3, 2025 release

To support patient access to Cancerguard, the Company recently announced an agreement with Quest Diagnostics to enable blood collection at the company’s approximately 7,000 patient access sites across the U.S., including through its patient service centers and in-office phlebotomists in provider offices, as well as mobile phlebotomy services for at-home collections. 2025 outlook The Company has updated its full-year 2025 revenue and adjusted EBITDA guidance: Prior guidance November 3 update Change at midpoint Y/Y growth rate Total revenue $3.130 - $3.170 billion $3.220 - $3.235 billion $77.5 million 17% Screening $2.440 - $2.470 billion $2.510 - $2.520 billion $60.0 million 20% Precision Oncology $690 - $700 million $710 - $715 million $17.5 million 9% Adjusted EBITDA $455 - $475 million $470 - $480 million $10.0 million 47% Third-quarter 2025 conference call & webcast Company management will host a conference call and webcast on Monday, November 3, 2025, at 5 p.m. ET to discuss third-quarter 2025 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international callers is 4437608. A replay of the webcast will be available at exactsciences.com. The webcast, conference call, and replay are open to all interested parties. Non-GAAP disclosure In addition to the Company's financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents the following non-GAAP measures: Core revenue — Core revenue is calculated to adjust for recent acquisitions and divestitures and foreign currency exchan